Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL
-
By
February 5, 2026
-
3 min
-
1
Combination of ponatinib and blinatumomab was tested in the trial.
-
2
Event-free survival was 87% for the experimental group.
-
3
This therapy resulted in a higher remission rate compared to traditional chemotherapy.
-
4
62% of control patients achieved MRD-negative status after crossover.
-
5
Serious adverse effects were manageable.
-
6
Findings could lead to a shift in treatment paradigms in Ph-positive ALL.
-
The phase III GIMEMA ALL2820 trial results reveal that a chemotherapy-free regimen, combining the TKI ponatinib and the bispecific T-cell engager blinatumomab, significantly outperformed the standard imatinib plus chemotherapy in adults with newly diagnosed Ph-positive acute lymphoblastic leukemia (ALL). This study demonstrated improved event-free survival and higher remission rates. Presented by Dr. Sabina Chiaretti at the 2025 ASH Annual Meeting, the trial suggests that targeted therapy combined with immunotherapy may become the favored first-line treatment for this patient population.
-
1
Combination of ponatinib and blinatumomab was tested in the trial.
-
2
Event-free survival was 87% for the experimental group.
-
3
This therapy resulted in a higher remission rate compared to traditional chemotherapy.
-
4
62% of control patients achieved MRD-negative status after crossover.
-
5
Serious adverse effects were manageable.
-
6
Findings could lead to a shift in treatment paradigms in Ph-positive ALL.
Listen Tab content
